Technical Analysis for ATNX - Athenex, Inc.

Grade Last Price % Change Price Change
D 5.01 -0.79% -0.04
ATNX closed down 0.79 percent on Friday, June 11, 2021, on 12 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical ATNX trend table...

Date Alert Name Type % Chg
Bearish Engulfing Bearish -0.79%
Narrow Range Bar Range Contraction -0.79%
NR7 Range Contraction -0.79%
Shooting Star Candlestick Bearish -1.76%
Up 3 Days in a Row Strength -1.76%
Upper Bollinger Band Touch Strength -1.76%
BB Squeeze Ended Range Expansion -0.60%
Crossed Above 20 DMA Bullish 1.83%
MACD Bullish Signal Line Cross Bullish 1.83%
Pocket Pivot Bullish Swing Setup 1.83%
Older End-of-Day Signals for ATNX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Athenex, Inc. Description

Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company offers Oraxol, an oral formulation of paclitaxel; Orateacan, an oral formulation of Irinotecan; Oradoxel, an oral formulation of Docetaxel, and an oral formulation of Topotecan for the treatment of various types of cancers. Its Src Kinase Inhibitors include KX-01 (KX2-391) and KX-02 (KX2-361) oncology drug candidates. The Company's Symptom Therapeutics include CQ-01, which is used for the treatment of burn pruritus and scars; CQ-R1, which is used for the treatment of an irradiation-induced dermatitis, and an intranasal Granisetron used for the treatment of chemotherapy-induced nausea/vomiting.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancers Oncology Organic Compounds Chemotherapy Radiation Antineoplastic Drugs Organic Chemistry Dermatitis Therapies For Cancer Nausea Docetaxel Pruritus Scars Treatment Of Various Types Of Cancers

Is ATNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 15.24
52 Week Low 3.66
Average Volume 6,393,718
200-Day Moving Average 9.53
50-Day Moving Average 4.47
20-Day Moving Average 4.84
10-Day Moving Average 4.89
Average True Range 0.30
ADX 21.06
+DI 24.67
-DI 15.44
Chandelier Exit (Long, 3 ATRs) 4.36
Chandelier Exit (Short, 3 ATRs) 5.36
Upper Bollinger Bands 5.18
Lower Bollinger Band 4.49
Percent B (%b) 0.75
BandWidth 14.33
MACD Line 0.11
MACD Signal Line 0.08
MACD Histogram 0.0272
Fundamentals Value
Market Cap 467.63 Million
Num Shares 93.3 Million
EPS -2.06
Price-to-Earnings (P/E) Ratio -2.44
Price-to-Sales 7.10
Price-to-Book 5.66
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.27
Resistance 3 (R3) 5.27 5.20 5.22
Resistance 2 (R2) 5.20 5.13 5.19 5.21
Resistance 1 (R1) 5.10 5.09 5.07 5.10 5.19
Pivot Point 5.03 5.03 5.01 5.02 5.03
Support 1 (S1) 4.93 4.96 4.90 4.93 4.83
Support 2 (S2) 4.86 4.92 4.85 4.81
Support 3 (S3) 4.76 4.86 4.80
Support 4 (S4) 4.76